Journal of Radiation Research
Online ISSN : 1349-9157
Print ISSN : 0449-3060
Regular Papers
Pretreatment with Rituximab Enhances Radiosensitivity of Non-Hodgkin's Lymphoma Cells
Ira SKVORTSOVABela-Andre POPPERSergej SKVORTSOVMaria SAURERThomas AUERRobert MOSERHans KAMLEITNERHeinz ZWIERZINAPeter LUKAS
Author information
JOURNAL FREE ACCESS

2005 Volume 46 Issue 2 Pages 241-248

Details
Abstract

The present study examines the effects of ionizing radiation in combination with rituximab (RTX), a chimeric human anti-CD20 monoclonal antibody, on proliferation, cell cycle distribution and apoptosis in B-lymphoma RL and Raji cells. Exposure to ionizing radiation (9 Gy) induced cell growth delay and apoptosis in RL cells, whereas Raji cells showed moderate radio-resistance. The simultaneous exposure of lymphoma cells to ionizing radiation and RTX (10 μg/mL) markedly enhanced apoptosis and cell growth delay in RL and Raji cells. Cooperative antiproliferative and apoptotic effects of RTX and radiation were achieved through the inhibition of c-myc and bcl-XL expression. Furthermore, RTX-modulated expression of cell cycle regulating proteins, such as p53, p21/WAF1, p27/KIP1, contributed to the development of radiation-induced cell killing and growth arrest. Each NHL cell line that underwent apoptosis induced by combination treatment revealed enhanced caspase-3 and poly (ADP-ribose) polymerase (PARP) cleavage as compared to only irradiated cells. These findings show that rituximab synergistically enhances radiation-induced apoptosis and cell growth delay through the expression of proteins involved in the programmed cell death and cell cycle regulation pathways.

Content from these authors

This article cannot obtain the latest cited-by information.

© 2005 by Journal of Radiation Research Editorial Committee
Previous article Next article
feedback
Top